With years upon years of first-hand experience in advancing the development of the modern medicine and drugs, we know how to make the world healthier!
In Women’s Health and Urology, ReHealth is focused on bringing new therapeutic options forward for under-treated or ignored conditions, such as uterine fibroids, Dyspareunia, nocturia, interstitial cystitis and Hunner lesions. Development programs include Ulipristal Acetate, a novel, non-surgical treatment for uterine fibroids, estradiol, a therapeutic treatment for painful sexual intercourse, SER-120, a low-dose desmopressin nasal spray) as a treatment for the symptoms of nocturia, and LiRIS, a novel lidocaine eluding stent for the treatment of interstitial cystitis and bladder pain syndrome.

Here's how it works:

ReHealth’s development efforts in anti-infectives are focused on bringing forward treatments for difficult to treat infections.
Lead programs include Ceftazidime/Avibactam, a potential treatment for hospital acquired bacteria pneumonia/ventilator acquired bacterial pneumonia.
Also we focus on Aztreonam/Avibactam, a novel treatment for gram-negative infections. ReHealth is also focused on adding new innovative programs throughout its seven therapeutic areas.

Apply for a Job with Us!

Each year we’ve got a lot of miscellaneous job offerings. See which ones are right for you!

Customers, who've done such transfers: